Keyword Analysis & Research: relay therapeutics
Keyword Research: People who searched relay therapeutics also searched
Search Results related to relay therapeutics on Search Engine
-
Relay Therapeutics
https://relaytx.com/
WEBOur Dynamo Platform. Relay Therapeutics® is creating new possibilities in drug discovery. Pipeline. We aim to drug the undruggable. We are advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease. Our Pipeline. Because you. can’t wait. Patients.
DA: 16 PA: 93 MOZ Rank: 40
-
Relay Therapeutics, Inc. (RLAY) - Yahoo Finance
https://finance.yahoo.com/quote/RLAY/
WEBRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule ...
DA: 26 PA: 34 MOZ Rank: 97
-
Our Science - Relay Therapeutics
https://relaytx.com/pipeline/
WEBRelay Therapeutics® is advancing a pipeline of promising therapeutic candidates designed to solve problems that were previously intractable or inadequately addressed with traditional drug discovery. Development Programs. We have deployed our Dynamo platform to initially focus on precision oncology.
DA: 40 PA: 13 MOZ Rank: 47
-
Who We Are - Relay Therapeutics
https://relaytx.com/who-we-are/
WEBRelay Therapeutics® is a clinical-stage precision medicine company that sits at the intersection of computational and experimental technologies. We are focused on making small molecule medicines against precision medicine targets with our objective being to make the discovery of medicines both more efficient and effective.
DA: 29 PA: 38 MOZ Rank: 1
-
Investors & Media | Relay Therapeutics
https://ir.relaytx.com/
WEBFeb 22, 2024 · Investors & Media | Relay Therapeutics. Company Overview. We are a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients.
DA: 14 PA: 30 MOZ Rank: 52
-
Relay Therapeutics Announces Initial Clinical Data Demonstrating …
https://finance.yahoo.com/news/relay-therapeutics-announces-initial-clinical-144000159.html
WEBORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
DA: 92 PA: 52 MOZ Rank: 56
-
Relay Therapeutics, Inc. (RLAY) - Yahoo Finance
https://finance.yahoo.com/quote/RLAY/profile/
WEBRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule...
DA: 73 PA: 10 MOZ Rank: 78
-
Relay Therapeutics to Announce First Quarter 2024 Financial …
https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announce-first-quarter-2024-financial-results
WEB4 days ago · Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary ...
DA: 74 PA: 97 MOZ Rank: 24
-
Why Relay Therapeutics Is Up 30% This Week | The Motley Fool
https://www.fool.com/investing/2021/10/15/why-relay-therapeutics-is-up-30-this-week/
WEBOct 15, 2021 · Relay Therapeutics is developing precision cancer drugs that can arrest troublesome proteins with a degree of specificity previously considered impossible. The stock surged this week in...
DA: 6 PA: 33 MOZ Rank: 78
-
Relay Therapeutics Company Profile - Craft
https://craft.co/relay-therapeutics
WEBRelay Therapeutics. Total Funding. $520 M. Revenue. $25.5 M. FY, 2023. Company Summary. Overview. Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients.
DA: 74 PA: 1 MOZ Rank: 93